ARCELLX AKTIEN News | A3DEJC Nachrichten

❌

Mehr »

Mittwoch, 19.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien

Doppeltes “STRONG BUY”! Jetzt bei EAM einsteigen?

	Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage


	Xetra-Orderbuch


	Fonds	Kurs	%


	Devisen	Kurs	%


	Rohstoffe	Kurs	%


	Themen	Kurs	%



Erweiterte Suche

Ad hoc-Mitteilungen:

Aktien»ARCELLX AKTIE»News

FN als Startseite

Branche

Biotechnologie

Aktienmarkt

NASDAQ Biotech

1-Jahres-Chart

5-Tage-Chart

Alle
Pressemitteilungen
Empfehlungen
Chartanalysen
Berichte

Zeit	Aktuelle Nachrichten Sprache: Alle DE EN	Leser	Medien
Di	The Latest Analyst Ratings For Arcellx	1	Benzinga.com
31.05.	Expert Ratings For Arcellx	3	Benzinga.com
14.05.	Analyst Expectations For Arcellx's Future	2	Benzinga.com
10.05.	Arcellx GAAP EPS of -$0.14, revenue of $39.3M	1	Seeking Alpha
09.05.	Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset	18	Seeking Alpha
09.05.	Arcellx, Inc. - 10-Q, Quarterly Report	1	SEC Filings
09.05.	Arcellx Provides First Quarter 2024 Financial Results	52	Business Wire	REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen
23.04.	Should You Be Bullish on Arcellx (ACLX)?	3	Insider Monkey
25.03.	Arcellx director sells over $35 million in company stock	1	Investing.com
19.03.	Arcellx CFO sells over $470k in company stock	1	Investing.com
18.03.	Arcellx director Ware sells over $630k in company stock	1	Investing.com
18.03.	Needham raises Arcellx stock target to $81, maintains buy rating	-	Investing.com
14.03.	Arcellx, Inc. - 8-K, Current Report	1	SEC Filings
07.03.	Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley	14	Benzinga.com
07.03.	Morgan Stanley bullish on Arcellx shares after myeloma data 'promising'	5	Investing.com
05.03.	Arcellx shares target raised by Truist on CAR-T potential	3	Investing.com
29.02.	Arcellx Analysts Boost Their Forecasts After Q4 Results	1	Benzinga.com
28.02.	Arcellx, Inc. - 8-K, Current Report	1	SEC Filings
28.02.	Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights	682	PR Newswire	-- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen
31.01.	Arcellx, Inc. - 8-K, Current Report	1	SEC Filings

Seite: 1 2 Weiter >>

26 Nachrichten in den letzten 12 Monaten

Unternehmen / Aktien	Aktienkurs	%	Top-Nachrichten
EPIGENOMICS	1,010	-25,46 %	EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024	EQS-News: Epigenomics AG / Schlagwort(e): Personalie Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 30.04.2024 / 15:00 CET/CEST Für den Inhalt... ► Artikel lesen
DEFENCE THERAPEUTICS	0,612	+0,66 %	EQS-News: Defence Therapeutics Inc.: Der wissenschaftliche Leiter von Defence, Dr. Moutih Rafei, spricht auf Money Talk Radio mit Ellis Martin über die Accum-Platform zur Krebsbekämpfung	EQS-News: Defence Therapeutics Inc. / Schlagwort(e): Sonstiges DER WISSENSCHAFTLICHE LEITER VON DEFENCE, DR. MOUTIH RAFEI, SPRICHT AUF MONEY TALK RADIO MIT... ► Artikel lesen
GINKGO BIOWORKS	0,392	-0,51 %	Ginkgo Bioworks Holdings, Inc. - 8-K, Current Report
BEAM THERAPEUTICS	23,170	0,00 %	Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease	MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported data highlighting... ► Artikel lesen
RECURSION PHARMACEUTICALS	9,700	+3,52 %	Recursion Pharmaceuticals: Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry	SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion... ► Artikel lesen
ONCOLYTICS BIOTECH	0,945	0,00 %	Oncolytics Biotech® Inc.: Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action	Trial-in-progress abstract highlights new cohort that could expand the company's pancreatic cancer program Pelareorep's ability to expand TILs highlights its immunotherapeutic mechanism... ► Artikel lesen
ASSERTIO	1,095	+4,29 %	Assertio Holdings And 2 Other Penny Stocks Insiders Are Buying
ARCTURUS THERAPEUTICS	25,960	0,00 %	Arcturus Therapeutics Holdings Inc. - 8-K, Current Report
VIR BIOTECHNOLOGY	8,950	-2,51 %	Vir Biotechnology, Inc.: Multiple Abstracts Highlighting Vir Biotechnology's Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024	- Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial - - Conference call scheduled for June 5, 2024, at 6:00 a.m. ET 12:00 p.m. CEST - Vir Biotechnology... ► Artikel lesen
SIGA TECHNOLOGIES	6,330	0,00 %	SIGA Technologies Inc.: SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
MERRIMACK PHARMACEUTICALS	15,130	0,00 %	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock	CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved... ► Artikel lesen
VERVE THERAPEUTICS	5,100	0,00 %	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen
ADMA BIOLOGICS	10,620	0,00 %	ADMA Biologics, Inc.: ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV & BIVIGAM	FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life Extends the Prior Room Temperature Storage Allowance for... ► Artikel lesen
ARS PHARMACEUTICALS	8,100	0,00 %	ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand	CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen
RELAY THERAPEUTICS	7,030	-0,85 %	Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608	CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge... ► Artikel lesen

ARCELLX INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 53,81 Euro und damit +0,11 % im Plus.

VerkaufenHaltenKaufen

■ Verkaufen

■ Halten

■ Kaufen

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und

ARCELLX INC

Aktuelle News zur ARCELLX Aktie

Aktuelle Kennzahlen zu ARCELLX